Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC

This study is testing a new cancer drug called LB-LR1109, which targets a protein on immune cells called LILRB (a receptor that can suppress the immune system's ability to fight cancer). In one part of the study it is tested alone in various solid tumors; in another part it is combined with atezolizumab (a standard immunotherapy drug) specifically in non-small cell lung cancer. Researchers want to find the right dose and see whether the drug is safe and effective. **You may be eligible if:** - You are 18 or older with confirmed advanced or metastatic solid cancer (Phase 1a: NSCLC, head and neck cancer, kidney cancer, bladder cancer, or melanoma) - Your cancer has progressed on or you are intolerant of standard therapies - You are in good physical condition (ECOG 0 or 1) with a life expectancy of at least 12 weeks - For Phase 1b: you have advanced NSCLC without targetable gene mutations and have measurable disease **You may NOT be eligible if:** - You have significant heart disease or heart failure - You have untreated or unstable brain metastases - You have another active cancer at the same time - You have previously received a therapy targeting LILRB Talk to your doctor to see if this trial is right for you.